Carl Dambkowski Sells 1,590 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 1,590 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total transaction of $48,463.20. Following the transaction, the insider now owns 251,033 shares of the company’s stock, valued at $7,651,485.84. The trade was a 0.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80.
• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.94, for a total transaction of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40.

Apogee Therapeutics Trading Up 2.0 %

APGE opened at $36.14 on Friday. The company’s 50 day moving average is $39.12 and its 200-day moving average is $47.02. Apogee Therapeutics, Inc. has a 1-year low of $29.10 and a 1-year high of $72.29. The company has a market cap of $1.63 billion, a P/E ratio of -14.93 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). On average, equities analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. boosted its position in Apogee Therapeutics by 162.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock worth $41,545,000 after buying an additional 438,036 shares during the period. Geode Capital Management LLC boosted its position in Apogee Therapeutics by 11.2% during the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after buying an additional 82,978 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Apogee Therapeutics by 17.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company’s stock worth $16,472,000 after buying an additional 41,686 shares during the period. Vestal Point Capital LP acquired a new stake in Apogee Therapeutics during the 3rd quarter worth approximately $8,018,000. Finally, Victory Capital Management Inc. boosted its position in Apogee Therapeutics by 121.6% during the 3rd quarter. Victory Capital Management Inc. now owns 346,358 shares of the company’s stock worth $20,345,000 after buying an additional 190,092 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on APGE. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Wedbush reissued an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research report on Monday, March 3rd. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Finally, Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $91.60.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.